Cardiovascular risk factors influence response to biological therapies in psoriasis. [electronic resource]
Producer: 20151006Description: 327-9 p. digitalISSN:- 1097-6787
- Adalimumab
- Adult
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Biological Therapy -- adverse effects
- Cardiovascular Diseases -- diagnosis
- Comorbidity
- Cross-Sectional Studies
- Dose-Response Relationship, Drug
- Etanercept
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin G -- administration & dosage
- Infliximab
- Male
- Middle Aged
- Psoriasis -- diagnosis
- Receptors, Tumor Necrosis Factor -- administration & dosage
- Retrospective Studies
- Risk Factors
- Severity of Illness Index
- Spain
- Time Factors
- Treatment Outcome
- Ustekinumab
No physical items for this record
Publication Type: Comparative Study; Letter; Observational Study
There are no comments on this title.
Log in to your account to post a comment.